omniture
logo
Search
北海康成制药有限公司
Media Room

Latest News

rss

CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1...

2023-10-17 08:00 10020

CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China

BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.H...

2023-10-16 13:38 1391

CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)

* LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS ...

2023-10-09 08:00 1542

CANbridge to Participate in Two Investor Conferences in September

BEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1...

2023-09-06 16:06 1640

CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023

BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbr...

2023-08-31 15:15 3952